Ther Adv Med Oncol: Bendamustine (bendamustine) combined with capecitabine in the treatment of treated patients with HER2-negative breast cancer

Bendamustine, a drug approved for the treatment of indolent non-Hodgkin's lymphoma
.

Studies have found that it exhibits anti-cancer activity in metastatic breast cancer (MBC)

Bendamustine, a drug approved for the treatment of indolent non-Hodgkin's lymphoma

AGMT MBC-6 (NCT01891227) is a multi-center, open-label, single-arm phase II study of patients with HER2-negative breast cancer
.

All patients have been treated with anthracyclines and/or taxanes

AGMT MBC-6 (NCT01891227) is a multi-center, open-label, single-arm phase II study of patients with HER2-negative breast cancer

From September 2013 to May 2015, 40 patients were screened, with a median age of 60 years (29-77)

Eighteen patients (45%) experienced at least one drug-related non-hematological AE (≥Grade 3) or hematological AE (≥Grade 4)

AEs

AEs

Efficacy evaluation showed that there were 17 PR cases and 1 CR case in the overall population, with an ORR of 45%; HR positive patients were 47% (14/30), and TNBC patients were 40% (4/10)
.

The CBR is 53% (21/40)

Efficacy evaluation showed that there were 17 PR cases and 1 CR case in the overall population, with an ORR of 45%; HR positive patients were 47% (14/30), and TNBC patients were 40% (4/10)

Efficacy evaluation

Efficacy assessment Efficacy assessment

In the overall population, the median OS was 19.
2 months (95% CI 14.
4-34.
8), the median PFS was 7.
5 months [95%CI 6.
1-10.
7], and the median PFS in HR-positive patients was 8.
4 months (95% CI 6.
1-12.
8), the median PFS of TNBC patients was 4.
1 months (95% CI 1.
4 -8.
9)
.

In an unplanned subgroup analysis of TP (thymidine phyosphorylase) expression, there was no difference between TP-positive and TP-negative patients [HR=0.

In the overall population, the median OS was 19.

           Prognosis

Prognosis

In summary, studies have shown that the combined application of capecitabine and bendamustine has a good effect and moderate toxicity
.

It is necessary to further explore this combination in the future

In summary, studies have shown that the combined application of capecitabine and bendamustine has a good effect and moderate toxicity
.
It is necessary to further explore this combination in the future
.
Studies have shown that the combined application of capecitabine and bendamustine has a good effect and moderate toxicity
.
It is necessary to further explore this combination in the future
.
Studies have shown that the combined application of capecitabine and bendamustine has a good effect and moderate toxicity
.
It is necessary to further explore this combination in the future
.

 

Original source:

Original source:

Rinnerthaler G, Gampenrieder SP, Petzer A, Hubalek M, Petru E, Sandholzer M, Andel J, Balic M, Melchardt T, Hauser-Kronberger C, Schmitt CA, Ulmer H, Greil R.
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).
Ther Adv Med Oncol.
2021 Oct 19;13:17588359211042301.
doi: 10.
1177/17588359211042301.
PMID: 34691243; PMCID: PMC8529308.

Rinnerthaler G, Gampenrieder SP, Petzer A, Hubalek M, Petru E, Sandholzer M, Andel J, Balic M, Melchardt T, Hauser-Kronberger C, Schmitt CA, Ulmer H, Greil R.
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).
Ther Adv Med Oncol.
2021 Oct 19;13:17588359211042301.
doi: 10.
1177/17588359211042301.
PMID: 34691243; PMCID: PMC8529308.
Leave a message here